Effect of Nintedanib on Quantitative CT in Patients With Progressive Pulmonary Fibrosis: Results from the INBUILD Trial

Authors:

Abstract
Rationale: In the placebo-controlled INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in subjects with progressive pulmonary fibrosis (PPF). We used data from a standardized non-contrast high-resolution chest computed tomography (HRCT) sub-study to compare two separate quantitative imaging analysis methods to assess the effects of nintedanib on disease progression. Methods: Subjects had a fibrosing ILD other than idiopathic pulmonary fibrosis and an extent of fibrosis on HRCT >10%. HRCT was acquired at screening/baseline and at weeks 24 and 52 in subjects who consented for the optional HRCT sub-study. We analyzed quantitative lung fibrosis and ILD scores (QLF/QILD) using an established quantitative CT method, and total disease extent (TDE) and weighted reticulovascular score (WRVS) using Brainomix e-Lung. Analyses were based on a linear mixed model for repeated measures for change from baseline in log10 transformed values. Estimates for group differences between nintedanib and placebo were back transformed to original scale. Results: Of 474 subjects recruited to the sub-study, 403 had QLF/QILD scores and 371 had e-Lung scores on baseline CT. Compared with baseline CT, both QILD score and e-Lung TDE demonstrated a significant reduction in extent of lung involvement in nintedanib vs. placebo groups at week 24 (-2.35%, p=0.0045 and -1.81%, p=0.0004, respectively) and at week 52 (-2.49%, p=0.0040 and -1.54%, p=0.0110, respectively). Whereas e-Lung WRVS demonstrated a significant difference in favor of nintedanib at week 24 (-0.71%, p=0.0204) and a numerical difference at week 52 (-0.54%, p=0.1787), QLF showed a significant difference of -1.30% (p=0.0152) in favor of nintedanib at week 52 and a numerical difference at week 24 (-0.87%, p=0.0986) (Table). Conclusion: Quantitative CT as assessed by QILD and e-Lung TDE demonstrated a beneficial effect of nintedanib on lung structure starting at week 24 and persisting through to week 52, further corroborating a slowing of disease progression in patients with PPF.